- Home
- CLM vs ELVN Comparison
CLM vs ELVN Comparison
Compare CLM & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLM | ELVN |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLM | ELVN |
|---|---|---|
| Price | $7.47 | $51.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.92 | $14.79 |
| 52 Week High | $8.53 | $52.39 |
Technical Indicators
Market Signals| Indicator | CLM | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 67.25 |
| Support Level | $7.33 | $25.63 |
| Resistance Level | $7.79 | N/A |
| Average True Range (ATR) | 0.09 | 2.68 |
| MACD | 0.01 | 0.44 |
| Stochastic Oscillator | 47.54 | 91.96 |
Price Performance
Historical ComparisonAbout CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.